Compare VITL & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VITL | RZLT |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.9M | 471.0M |
| IPO Year | 2020 | 2011 |
| Metric | VITL | RZLT |
|---|---|---|
| Price | $9.42 | $4.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $13.22 | $9.80 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.03 | ★ 23.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $759,444,000.00 | N/A |
| Revenue This Year | $1.33 | N/A |
| Revenue Next Year | $7.03 | $2,481.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $7.95 | $1.07 |
| 52 Week High | $43.80 | $11.46 |
| Indicator | VITL | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 66.61 |
| Support Level | $8.73 | $4.36 |
| Resistance Level | $13.71 | $5.43 |
| Average True Range (ATR) | 0.53 | 0.31 |
| MACD | -0.03 | 0.11 |
| Stochastic Oscillator | 17.69 | 93.48 |
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.